Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer

BACKGROUND: The antibody cetuximab, targeting epidermal growth factor receptor (EGFR), is used to treat metastatic colorectal cancer (mCRC). Clinical trials suggest reduced benefit from the combination of cetuximab with oxaliplatin. The aim of this study was to investigate potential negative interac...

Descripción completa

Detalles Bibliográficos
Autores principales: Santoro, Valeria, Jia, Ruochen, Thompson, Hannah, Nijhuis, Anke, Jeffery, Rosemary, Kiakos, Konstantinos, Silver, Andrew R., Hartley, John A., Hochhauser, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864961/
https://www.ncbi.nlm.nih.gov/pubmed/26719345
http://dx.doi.org/10.1093/jnci/djv394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864961/
https://www.ncbi.nlm.nih.gov/pubmed/26719345
http://dx.doi.org/10.1093/jnci/djv394

Ejemplares similares